[go: up one dir, main page]

MX2016004964A - Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo. - Google Patents

Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.

Info

Publication number
MX2016004964A
MX2016004964A MX2016004964A MX2016004964A MX2016004964A MX 2016004964 A MX2016004964 A MX 2016004964A MX 2016004964 A MX2016004964 A MX 2016004964A MX 2016004964 A MX2016004964 A MX 2016004964A MX 2016004964 A MX2016004964 A MX 2016004964A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
fused heterocyclic
preparation
pharmaceutical composition
formula
Prior art date
Application number
MX2016004964A
Other languages
English (en)
Other versions
MX381304B (es
Inventor
Zusheng Xu
Yangtong Lou
Original Assignee
Shanghai Yingli Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yingli Pharm Co Ltd filed Critical Shanghai Yingli Pharm Co Ltd
Publication of MX2016004964A publication Critical patent/MX2016004964A/es
Publication of MX381304B publication Critical patent/MX381304B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describe un compuesto heterocíclico fusionado, un método de preparación del mismo, una composición farmacéutica y usos del mismo; el compuesto heterocíclico fusionado se muestra en la fórmula I, fórmula II o fórmula III; el método de preparación del compuesto heterocíclico fusionado y/o sal farmacéuticamente aceptable del mismo en la presente invención se compone de tres rutas de síntesis; la presente invención también proporciona una composición farmacéutica del compuesto heterocíclico fusionado, la composición farmacéutica que contiene uno o más del compuesto heterocíclico fusionado se muestra en la fórmula I, fórmula II, o fórmula III, la sal farmacéuticamente aceptable del mismo, hidratos, compuesto solvente, polimorfos y profármacos del mismo y un portador farmacéuticamente aceptable; la presente invención también se refiere a una aplicación del compuesto heterocíclico fusionado y/o la composición farmacéutica en la preparación de inhibidores de quinasa y en la preparación de fármacos para prevenir y tratar enfermedades relacionadas con la quinasa; el compuesto heterocíclico fusionado de la presente invención tiene la función de inhibición selectiva en PI3Kd, y puede utilizarse para la preparación de fármacos para prevenir y tratar enfermedades de proliferación celular tales como cánceres, infecciones, inflamaciones o enfermedades autoinmunes.(ver Fórmulas).
MX2016004964A 2013-10-16 2014-09-19 Compuesto heterocíclico fusionado, método de preparación del mismo, composición farmacéutica, y usos del mismo. MX381304B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310485200 2013-10-16
PCT/CN2014/086914 WO2015055071A1 (zh) 2013-10-16 2014-09-19 稠合杂环化合物、其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
MX2016004964A true MX2016004964A (es) 2016-07-11
MX381304B MX381304B (es) 2025-03-12

Family

ID=52827649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004964A MX381304B (es) 2013-10-16 2014-09-19 Compuesto heterocíclico fusionado, método de preparación del mismo, composición farmacéutica, y usos del mismo.

Country Status (14)

Country Link
US (1) US9656996B2 (es)
EP (1) EP3059238B1 (es)
JP (1) JP6139789B2 (es)
KR (1) KR101982912B1 (es)
CN (3) CN106831722B (es)
AU (1) AU2014336775B2 (es)
CA (1) CA2926596C (es)
IL (1) IL245112B (es)
MX (1) MX381304B (es)
NZ (1) NZ718487A (es)
RU (1) RU2663999C2 (es)
SG (1) SG11201602446VA (es)
TW (1) TWI631115B (es)
WO (1) WO2015055071A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
US10765681B2 (en) 2016-02-05 2020-09-08 Academia Sinica Purine compounds possessing anticancer activity
LT3472160T (lt) * 2016-06-16 2021-04-26 Janssen Pharmaceutica Nv Biciklinio piridino, pirazino ir pirimidino dariniai kaip pi3k beta inhibitoriai
AU2018246321B2 (en) 2017-03-29 2021-07-29 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
SG11202103118PA (en) * 2018-09-27 2021-04-29 Shanghai Yingli Pharmaceutical Co Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
KR102405055B1 (ko) 2019-01-16 2022-06-07 상하이 잉리 파마슈티컬 컴퍼니 리미티드 모르폴리노퀴나졸린 화합물의 제조방법 및 이의 중간체
CN111848598B (zh) * 2019-04-26 2024-12-10 健艾仕生物医药有限公司 一种含杂环的化合物、其应用及含其的组合物
CN111943938A (zh) * 2019-05-17 2020-11-17 上海再极医药科技有限公司 一种a2a腺苷受体拮抗剂的合成方法
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN113444073B (zh) * 2020-03-26 2024-01-05 上海璎黎药业有限公司 吗啉基喹唑啉类化合物的晶型ⅲ、其制备方法及应用
WO2022199373A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用
WO2022199375A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物的药物组合物及其制备方法
WO2022228218A1 (zh) * 2021-04-30 2022-11-03 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用
JP2024520000A (ja) * 2021-05-24 2024-05-21 上海瓔黎薬業有限公司 含窒素複素環化合物、その製造方法及び使用
WO2023030437A1 (zh) * 2021-09-01 2023-03-09 江苏恒瑞医药股份有限公司 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途
WO2023165571A1 (zh) 2022-03-04 2023-09-07 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1277738B1 (en) * 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
CN101068551A (zh) 2004-12-03 2007-11-07 默克公司 喹啉速激肽受体拮抗剂
UA116188C2 (uk) 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
CN101511840A (zh) 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
US8022205B2 (en) * 2006-08-08 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivatives as PI3K inhibitor and use thereof
MX2009005360A (es) 2006-11-20 2009-06-05 Novartis Ag Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinol in-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propion itrilo.
SI2139483T1 (sl) 2007-04-11 2013-11-29 Exelixis, Inc. Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
CA2704711C (en) * 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
KR101643237B1 (ko) 2007-10-05 2016-07-27 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
CA2743015A1 (en) 2008-11-11 2010-05-20 Xcovery Holding Company Llc Pi3k/mtor kinase inhibitors
KR20110114663A (ko) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
ES2500643T3 (es) * 2009-04-03 2014-09-30 Verastem, Inc. Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120994A2 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
JP2012531436A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
US8569296B2 (en) 2009-09-29 2013-10-29 Xcovery Holding Company, Llc PI3K (delta) selective inhibitors
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CA2786294A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
JP2013529212A (ja) 2010-05-19 2013-07-18 エクスカバリー ホールディング カンパニー，エルエルシー ｍＴＯＲ選択的キナーゼ阻害剤
US8293736B2 (en) 2010-07-14 2012-10-23 F. Hoffmann La Roche Ag Purine compounds selective for PI3K P110 delta, and methods of use
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
WO2012032065A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
ES2612503T3 (es) 2010-09-14 2017-05-17 Exelixis, Inc. Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
EP2619209A1 (en) 2010-09-24 2013-07-31 Gilead Calistoga LLC Atropisomers of pi3k-inhibiting compounds
PL3040333T3 (pl) * 2010-10-01 2019-03-29 Novartis Ag Krystaliczne postacie 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4-trifluorometylopirydyno-2-aminy, inhibitora pik3
CN103124496B (zh) 2010-10-06 2016-03-30 葛兰素史密丝克莱恩有限责任公司 作为pi3激酶抑制剂的苯并咪唑衍生物
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
JP2014510122A (ja) 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
FR2986232B1 (fr) 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
EP3059238B1 (en) 2020-05-27
CN106831722A (zh) 2017-06-13
TW201518288A (zh) 2015-05-16
KR101982912B1 (ko) 2019-09-10
RU2016115934A (ru) 2017-11-20
HK1209738A1 (en) 2016-04-08
CN104557872A (zh) 2015-04-29
CN106831721A (zh) 2017-06-13
AU2014336775B2 (en) 2018-04-05
EP3059238A4 (en) 2017-04-12
TWI631115B (zh) 2018-08-01
RU2663999C2 (ru) 2018-08-14
IL245112B (en) 2020-10-29
KR20160062170A (ko) 2016-06-01
EP3059238A1 (en) 2016-08-24
MX381304B (es) 2025-03-12
IL245112A0 (en) 2016-06-30
SG11201602446VA (en) 2016-05-30
JP6139789B2 (ja) 2017-05-31
US9656996B2 (en) 2017-05-23
AU2014336775A1 (en) 2016-04-21
CN104557872B (zh) 2017-05-24
NZ718487A (en) 2020-01-31
CA2926596C (en) 2020-07-14
CA2926596A1 (en) 2015-04-23
US20160244432A1 (en) 2016-08-25
WO2015055071A1 (zh) 2015-04-23
CN106831722B (zh) 2019-08-30
CN106831721B (zh) 2019-10-22
JP2016533372A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
MX2016004964A (es) Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
DOP2015000202A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
PE20151448A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
MX377124B (es) Compuestos heterociclicos y usos de los mismos.
CU20140143A7 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CR20150045A (es) Inhibidores de hepatitis c
CL2015002932A1 (es) Inhibidores de proteína quinasa
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
MX2021001231A (es) Compuestos heterociclicos y sus usos.
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
CL2017001761A1 (es) Péptidos antagonistas prgc